Synairgen’s Inhaled COVID-19 Treatment Found to Reduce Risk of Severe Disease

Synairgen has released the results of a phase 2 clinical trial in which its inhaled interferon beta demonstrated benefit in hospitalized COVID-19 patients.

The trial of 101 patients found that SNG001 reduced the risk of developing severe disease by 79 percent compared to a placebo. People given the treatment were also more than twice as likely to recover over the course of treatment than those given a placebo.  

There were no deaths among patients given SNG001 compared to three among those given a placebo.